IL265911A - Epilimod preparations and methods of using them in the treatment of Alzheimer's disease - Google Patents
Epilimod preparations and methods of using them in the treatment of Alzheimer's diseaseInfo
- Publication number
- IL265911A IL265911A IL265911A IL26591119A IL265911A IL 265911 A IL265911 A IL 265911A IL 265911 A IL265911 A IL 265911A IL 26591119 A IL26591119 A IL 26591119A IL 265911 A IL265911 A IL 265911A
- Authority
- IL
- Israel
- Prior art keywords
- alzheimer
- disease
- treatment
- methods
- same
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229950002889 apilimod Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407186P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056147 WO2018071548A1 (en) | 2016-10-12 | 2017-10-11 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL265911A true IL265911A (en) | 2019-06-30 |
Family
ID=60268450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265911A IL265911A (en) | 2016-10-12 | 2019-04-08 | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190365771A1 (enExample) |
| EP (1) | EP3525794A1 (enExample) |
| JP (1) | JP7199349B2 (enExample) |
| KR (1) | KR20190067824A (enExample) |
| CN (1) | CN110167559A (enExample) |
| AU (1) | AU2017342262B2 (enExample) |
| BR (1) | BR112019007214A2 (enExample) |
| CA (1) | CA3039199A1 (enExample) |
| IL (1) | IL265911A (enExample) |
| MX (1) | MX2019004179A (enExample) |
| RU (1) | RU2019113752A (enExample) |
| WO (1) | WO2018071548A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111801098A (zh) | 2018-02-21 | 2020-10-20 | 人工智能治疗公司 | 使用阿匹莫德和谷氨酸能剂的组合疗法 |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| MX2022008627A (es) | 2020-01-13 | 2022-11-08 | Verge Analytics Inc | Pirazolo-pirimidinas sustituidas y usos de las mismas. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
| TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| DE112012000404T5 (de) | 2011-01-04 | 2014-04-17 | Charitè Universitätsmedizin Berlin | Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer |
| PL3215158T3 (pl) * | 2014-11-07 | 2019-11-29 | Ai Therapeutics Inc | Apilimod do zastosowania do leczenia raka nerki |
| CN107206090A (zh) * | 2014-11-07 | 2017-09-26 | 拉姆医疗公司 | 阿匹莫德在结肠直肠癌治疗中的用途 |
| US10729694B2 (en) * | 2015-01-23 | 2020-08-04 | AI Therapeutics, Inc. | Anti-viral compositions containing PIKfyve inhibitors and use thereof |
| WO2016126707A1 (en) * | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| WO2016210372A2 (en) * | 2015-06-25 | 2016-12-29 | University Of Southern California | Methods to treat neurological diseases |
-
2017
- 2017-10-11 US US16/340,845 patent/US20190365771A1/en not_active Abandoned
- 2017-10-11 AU AU2017342262A patent/AU2017342262B2/en not_active Ceased
- 2017-10-11 BR BR112019007214A patent/BR112019007214A2/pt not_active Application Discontinuation
- 2017-10-11 KR KR1020197012287A patent/KR20190067824A/ko not_active Ceased
- 2017-10-11 CN CN201780076520.2A patent/CN110167559A/zh active Pending
- 2017-10-11 RU RU2019113752A patent/RU2019113752A/ru not_active Application Discontinuation
- 2017-10-11 WO PCT/US2017/056147 patent/WO2018071548A1/en not_active Ceased
- 2017-10-11 JP JP2019519652A patent/JP7199349B2/ja active Active
- 2017-10-11 EP EP17794818.9A patent/EP3525794A1/en not_active Withdrawn
- 2017-10-11 MX MX2019004179A patent/MX2019004179A/es unknown
- 2017-10-11 CA CA3039199A patent/CA3039199A1/en active Pending
-
2019
- 2019-04-08 IL IL265911A patent/IL265911A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017342262B2 (en) | 2023-09-28 |
| BR112019007214A2 (pt) | 2019-07-02 |
| WO2018071548A1 (en) | 2018-04-19 |
| US20190365771A1 (en) | 2019-12-05 |
| JP2019530711A (ja) | 2019-10-24 |
| RU2019113752A3 (enExample) | 2021-01-19 |
| CA3039199A1 (en) | 2018-04-19 |
| MX2019004179A (es) | 2019-09-02 |
| KR20190067824A (ko) | 2019-06-17 |
| RU2019113752A (ru) | 2020-11-13 |
| JP7199349B2 (ja) | 2023-01-05 |
| EP3525794A1 (en) | 2019-08-21 |
| AU2017342262A1 (en) | 2019-04-18 |
| CN110167559A (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276315A (en) | Donepezil preparations and a method for treating Alzheimer's disease | |
| IL260352B (en) | Methods and preparations for the treatment of neurological disease | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| EP3558340A4 (en) | METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
| EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| HUE058749T2 (hu) | Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| HUE056265T2 (hu) | Igmezin Alzheimer-kór kezelésében történõ alkalmazásra | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| EP3137097C0 (en) | TREATMENT AND PREVENTION OF ALZHEIMER | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease | |
| EP3261655A4 (en) | Compositions and methods for the treatment of "plaques and tangles" in humans and animals | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| SMT202100070T1 (it) | Complesso e composizioni per il trattamento di affezioni oculari e cutanee | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| HUE037501T2 (hu) | Alzheimer-kór (AD) kezelése és megelõzése | |
| HK40013419A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| GB201710410D0 (en) | Inorganic polyphosphate formulations for use in the treatment of alzheimer disease |